Ignite Creation Date:
2025-12-24 @ 3:44 PM
Ignite Modification Date:
2026-02-21 @ 5:10 AM
Study NCT ID:
NCT03824392
Status:
COMPLETED
Last Update Posted:
2023-07-18
First Post:
2019-01-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Sponsor:
aTyr Pharma, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pulmonary Sarcoidosis | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Pulmonary Sarcoidosis | View |
| None | Resokine | View |
| None | Sarcoidosis | View |
| None | Granulomas | View |
| None | Inflammation | View |
| None | Lymphoproliferative Disorders | View |
| None | Interstitial Lung Disease | View |
| None | Neuropilin-2 | View |
| None | Steroids | View |
| None | Oral corticosteroids | View |
| None | Immunomodulatory | View |
| None | tRNA Synthetase | View |
| None | ATYR1923 (efzofitimod) | View |